Judge Says Biosimilars Law Prohibits Premature Patent Suit

Washington Drug Letter
A California judge has ruled that Sandoz must file an application with the FDA for approval of a biosimilar referencing Amgen’s biologic arthritis drug Enbrel before it can challenge the brand drug’s patents.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00